Interestingly, a DRD2 antagonist and modulator only partially mitigated the suppressive effect of ROPI on the ALS phenotype, and the detailed mechanism of ROPI activity remains unclear. The gene discussed is DRD2; the disease is amyotrophic lateral sclerosis.